ArticleNature metabolism2026
A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Article in Nature metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026Trial
- Lipid sensing and brain hormone receptors in food intake and glucose regulation.Nature reviews. Endocrinology · 2026Review
- Amylin: A Multi-Functional Pancreatic Hormone-A Review.Diabetes, obesity & metabolism · 2026Review
- Single-cell profiling identifies obesity-disrupted brain glucose sensing.Nature communications · 2026Article
- Functional segregation of body-brain signals in the area postrema.bioRxiv : the preprint server for biology · 2026Article
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.Nature metabolism · 2026Article
- Cellular loci for cagrilintide action identified.Nature metabolism · 2026Article
- Interoceptive processing in the nucleus of the solitary tract.Current opinion in neurobiology · 2025Review
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025Article
Corrections and comments
- Update of
Authors and funding
31 authors.
Funding
Abstract
Amylin receptor agonists such as cagrilintide represent emerging obesity therapies. To understand mediators of cagrilintide action, we generated a transcriptomics atlas of over 530,000 cells comprising 80 neuronal cell populations across rat, mouse and macaque caudal brainstem, with spatial profiling to map distribution in the rat dorsal vagal complex (DVC). Here we show that cagrilintide regulates two conserved Calcr-expressing DVC neuronal populations. While acute cagrilintide treatment alters gene expression in area postrema Calcr/Ramp3 neurons, chemogenetic activation in rats fails to affect long-term food intake and body weight. In contrast, long-term cagrilintide treatment in rats upregulates prolactin-releasing hormone (Prlh) expression in nucleus of the solitary tract Calcr/Prlh cells that are conserved across rodents, macaques and humans. Knocking down DVC Prlh abrogates the effects of cagrilintide but not semaglutide in rats. Our study provides a cross-species spatially resolved atlas of DVC cell populations and defines Calcr/Prlh neurons as mediators of amylin receptor agonist action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.